Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
544759 GLPL

Goldline Pharmaceutical Share Price

 
Stock touched all time low

 

Goldline Pharmaceutical live price: ₹41.76. It opened at ₹42 vs previous close ₹44; intraday high/low: ₹42/₹42.

Goldline Pharmaceutical Performance

  • Today's Low
  • ₹42
  • Today's High
  • ₹42
  • 52 Week Low
  • ₹42
  • 52 Week High
  • ₹60
  • Open Price₹42
  • Previous Close₹44
  • Volume78,000
  • 50 DMA-
  • 100 DMA-
  • 200 DMA-

Goldline Pharmaceutical Chart

Investment Returns

Smart Investing Starts Here Start SIP with Goldline Pharmaceutical for Steady Growth!

Invest Now

Goldline Pharmaceutical Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 14.2
  • PEG Ratio
  • -
  • Market Cap Cr
  • 40
  • P/B Ratio
  • 3
  • Average True Range
  • -
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • -
  • MFI
  • -

Goldline Pharmaceutical Financials

Goldline Pharmaceutical Technicals

EMA & SMA

Current Price
₹41.76
-2.19 (-4.98%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 0
  • 20 Day
  • -
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

43.95 Pivot Speed
  • R3 43.95
  • R2 43.95
  • R1 43.95
  • S1 43.95
  • S2 43.95
  • S3 43.95

Goldline Pharmaceutical Shareholding Pattern

57.29%
5.16%
0.09%
25.14%
12.32%

Goldline Pharmaceutical FAQs

Goldline Pharmaceutical share price is ₹41 As on 27 May, 2026 | 09:37

The Market Cap of Goldline Pharmaceutical is ₹40.1 Cr As on 27 May, 2026 | 09:37

The P/E ratio of Goldline Pharmaceutical is 14.2 As on 27 May, 2026 | 09:37

The PB ratio of Goldline Pharmaceutical is 3 As on 27 May, 2026 | 09:37

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23